{"organizations": [], "uuid": "75ea1fa4ac9eb49126164b6979759b3da8a14796", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530588?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Series A lands $22mm for SutroVax", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Series A lands $22mm for SutroVax", "spam_score": 0.0, "site_type": "news", "published": "2015-07-25T02:40:00.000+03:00", "replies_count": 0, "uuid": "75ea1fa4ac9eb49126164b6979759b3da8a14796"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530588?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Series A lands $22mm for SutroVax", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Series A lands $22mm for SutroVax Deal Date: Jul-01-2015 / Deal # 201530588 Executive Summary \nInfectious disease vaccines developer SutroVax Inc. raised $22mm in its Series A financing led by Abingworth, which was joined by Longitude Capital, Roche Venture Fund, and CTI Life Sciences Fund. Proceeds will help fund vaccine candidates through preclinical proof-of-concept. A representative from Abingworth joins SutroVax's board as interim chairman, and a member from both Longitude Capital and Roche Venture will take board seats.", "external_links": [], "published": "2015-07-25T02:40:00.000+03:00", "crawled": "2015-07-25T14:36:00.592+03:00", "highlightTitle": ""}